| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 6123264 | Journal of Infection | 2014 | 5 Pages |
Abstract
Our findings strongly suggest that patients who relapse after first treatment, particularly those infected with HCV genotype 2-3, or living in countries with no access to the direct acting antiviral drugs for HCV, could be successfully re-treated with standard bi-therapy of PEG-IFNÂ +Â RBV regimen.
Keywords
Related Topics
Life Sciences
Immunology and Microbiology
Applied Microbiology and Biotechnology
Authors
Evguenia Krastinova, Firouzé Bani-Sadr, Delphine Fromentin, Cécile Goujard, Mojgan Hessamfar, Yazdan Yazdanpanah, Stanislas Pol, Patrice Cacoub, Christian Perronne, Fabrice Carrat,